Treatment/targets | Sponsor | ClinicalTrials.gov identifier | Phase | PCD | n | Treatment regimen and latest results |
Sitravatinib Tyro3, Axl, MerTK, VEGFR2, PDGFR, KIT, FLT3, MET, RET | Mirati Therapeutics, Inc. | NCT02954991 | 2 | 05/2021 | 206* | Sitravatinib + nivolumab arm After a median follow-up of 28 mo, among 68 pts with prior clinical benefit from CPI:96
|
Mirati Therapeutics, Inc. and Bristol-Myers Squibb | NCT03906071 | 3 | 09/2022 | 532† | SAPPHIRE:97 Sitravatinib + nivolumab versus docetaxel | |
BeiGene | NCT04921358 | 3 | 06/2024 | 420† | Sitravatinib + tislelizumab versus docetaxel | |
Cabozantinib Tyro3, Axl, MerTK, VEGFR2, KIT, FLT3, MET, RET | Exelixis | NCT03170960 | 1–2 | 12/2021 | 1732† | COSMIC-021: Cabozantinib + atezolizumab88 After a median follow-up of 8.9 months (n=30):
|
Roche/Exelixis | NCT04471428 | 3 | 09/2022 | 366* | CONTACT-01: Cabozantinib + atezolizumab vs docetaxel | |
Bemcentinib Axl | BerGenBio/ Merck Sharp & Dohme | NCT03184571 | 2 | 09/2022 | 106† | Bemcentinib + pembrolizumab106 114 After a median treatment duration of 8.9 weeks, among CPI-refractory pts (Cohort B) with cAxl-positive tumors (n=7):
|
BA3011 Axl | BioAlta | NCT04681131 | 2 | 12/2022 | 240† | BA3011 monotherapy BA3011 + PD-1 inhibitor |
INCB081776 Axl, MerTK | Incyte Corporation | NCT03522142 | 1 | 09/2022 | 140† | INCB081776 + retifanlimab (INCMGA00012)89 |
PF-07265807/ARRAY-067 Axl, MerTK | Pfizer | NCT04458259 | 1 | 01/2024 | 115† | PF-07265807 + sasanlimab arm109 |
*Actual enrolment.
†Estimated enrolment.
CBR, clinical benefit rate; CPI, checkpoint inhibitor; CR, complete response; DCR, disease control rate; FLT3, FMS-like tyrosine kinase; KIT, KIT proto-oncogene RTK; MET, hepatocyte growth factor receptor; mOS, median overall survival; mPFS, median progression-free survival; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PCD, primary completion date; PDGFR, platelet-derived growth factor receptor; PR, partial response; pts, patients; RET, rearranged during transfection; TAM, Tyro3, Axl, MerTK; VEGFR2, vascular endothelial growth factor receptor 2.